菜单

Webinar

Tailored Bioassay Solutions for Peptide Drugs and New Modality Biologics
May 7, 2026
Tailored Bioassay Solutions for Peptide Drugs and New Modality Biologics

Webinar title:

Tailored Bioassay Solutions for Peptide Drugs and New Modality Biologics

 

Abstract:

Peptide, peptide conjugated, and other complex molecule therapeutics present modality specific CMC challenges. Specifically, they require precise, mechanism aligned characterization of biological activity, structural integrity, and impurity driven functional risk.

 

Leveraging experience across 450 product specific potency assays and more than 300 therapeutic targets, WuXi Biologics has established an integrated bioassay solution. Tailored to peptide drugs, our solution combines GPCR mediated signaling assays, engineered reporter gene systems, kinetic SPR binding analyses, and Fc effector function profiling to deliver MOA-representative assessment, accelerate CMC development, and reduce regulatory risk.

 

Watch on-demand today and gain the following insights:

 

  • Advanced bioassay solutions that navigate regulatory and impurity control challenges
  • Comprehensive, tailored bioassay approaches for complex MOAs and next-generation peptide modalities
  • WuXi Biologics’ expertise in GLP-1 therapeutics, demonstrated through a case study

 

Watch On-Demand